Martin Williams

Martin Williams, PhD is a Senior Research Fellow at the Centre for Mental Health, Swinburne University. Martin’s research background is in Medicinal Chemistry and Pharmacology, and he is Executive Director of Psychedelic Research in Science & Medicine (PRISM) and Vice-President of Entheogenesis Australis (EGA). Martin has been a co-investigator on a number of Australian clinical trials of psychedelic-assisted psychotherapy, including the St Vincent’s Hospital Melbourne study of psilocybin-assisted psychotherapy in palliative care; the Monash PsiConnect neuroimaging study of psilocybin with mindfulness meditation; the Swinburne PsiloDep pilot study; and several other studies of psilocybin, MDMA and other psychedelics for the treatment of a range of mental health conditions.

Martin has been an articulate advocate for psychedelic medical research and the evidence-based clinical translation of psychedelic-assisted therapies for almost twenty years. He has co-authored numerous academic papers providing an Australian perspective on psychedelic therapies, including an influential Perspectives paper in Frontiers in Psychiatry, and was co-editor of the special topic issue of Frontiers, Beyond Psilocybin: Exploring the Clinical Potential of Novel and Alternative Psychedelics. Martin has an ongoing interest in contributing to the careful, pragmatic translation of psychedelic medicine from research to clinical practice.

Connect: www.prism.org.au